Lumen News

Lumen News image

Lumen News image

Lumen and Novo Nordisk link up on oral biologics for cardiometabolic disease

Lumen and Novo Nordisk link up on oral biologics for cardiometabolic disease

June 16, 2021

Ultra-Rapid, Low-Cost Neutralizing Antibody Therapeutic for COVID-19

Ultra-Rapid, Low-Cost Neutralizing Antibody Therapeutic for COVID-19

March 18, 2021

Beyond the lung: treating the GI symptoms of Covid-19

Beyond the lung: treating the GI symptoms of Covid-19

February 16, 2021

High Impact Drugs at Dirt Cheap Cost

High Impact Drugs at Dirt Cheap Cost

February 12, 2021

CARB-X awards $5.3M to Lumen for diarrheal disease research, development

CARB-X awards $5.3M to Lumen for diarrheal disease research, development

February 12, 2021

Lumen Bioscience reels in $16M Series B to democratize biologics

Lumen Bioscience reels in $16M Series B to democratize biologics

November 23, 2020

Lumen bags U.S. grant for GI-focused COVID-19 antibody cocktail

Lumen bags U.S. grant for GI-focused COVID-19 antibody cocktail

November 23, 2020

With a $4M federal grant, Lumen jumps into the Covid-19 treatment race

With a $4M federal grant, Lumen jumps into the Covid-19 treatment race

November 23, 2020

Q and A with Lumen: using spirulina to manufacture Covid-19 antibodies

Q and A with Lumen: using spirulina to manufacture Covid-19 antibodies

November 11, 2020